Moreover, and according to the NIA-AA Research Framework (which defines AD as a biological construct documented in vivo by biomarker evidence of both Aβ [A] and tau pathology [T]) [5], we propose that plasma NTA-tau may be a more suitable plasma T biomarker in AD than the ones currently used. This evidence concerns the gene MAPT and Alzheimer disease.